Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis

任天堂 特发性肺纤维化 医学 吡非尼酮 肺纤维化 纤维化 贾纳斯激酶 临床试验 癌症研究 免疫学 病理 内科学 细胞因子
作者
Yue Li,Congshan Jiang,Wenhua Zhu,Shemin Lu,Hongchuan Yu,Liesu Meng
出处
期刊:Science Progress [SAGE Publishing]
卷期号:107 (2) 被引量:2
标识
DOI:10.1177/00368504241247402
摘要

Idiopathic pulmonary fibrosis is a chronic and progressive interstitial lung disease with a poor prognosis. Idiopathic pulmonary fibrosis is characterized by repeated alveolar epithelial damage leading to abnormal repair. The intercellular microenvironment is disturbed, leading to continuous activation of fibroblasts and myofibroblasts, deposition of extracellular matrix, and ultimately fibrosis. Moreover, pulmonary fibrosis was also found as a COVID-19 complication. Currently, two drugs, pirfenidone and nintedanib, are approved for clinical therapy worldwide. However, they can merely slow the disease's progression rather than rescue it. These two drugs have other limitations, such as lack of efficacy, adverse effects, and poor pharmacokinetics. Consequently, a growing number of molecular therapies have been actively developed. Treatment options for IPF are becoming increasingly available. This article reviews the research platform, including cell and animal models involved in molecular therapy studies of idiopathic pulmonary fibrosis as well as the promising therapeutic targets and their development progress during clinical trials. The former includes patient case/control studies, cell models, and animal models. The latter includes transforming growth factor-beta, vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, lysophosphatidic acid, interleukin-13, Rho-associated coiled-coil forming protein kinase family, and Janus kinases/signal transducers and activators of transcription pathway. We mainly focused on the therapeutic targets that have not only entered clinical trials but were publicly published with their clinical outcomes. Moreover, this work provides an outlook on some promising targets for further validation of their possibilities to cure the disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ukiss完成签到 ,获得积分10
刚刚
tejing1158发布了新的文献求助30
2秒前
研友_8DAv0L完成签到,获得积分10
4秒前
科研通AI5应助科研通管家采纳,获得10
4秒前
4秒前
FashionBoy应助科研通管家采纳,获得10
4秒前
4秒前
科研通AI5应助科研通管家采纳,获得10
4秒前
NexusExplorer应助科研通管家采纳,获得10
4秒前
Lasse应助科研通管家采纳,获得10
4秒前
研友_VZG7GZ应助科研通管家采纳,获得10
4秒前
852应助科研通管家采纳,获得10
4秒前
wanci应助科研通管家采纳,获得10
4秒前
小二郎应助科研通管家采纳,获得10
4秒前
今后应助科研通管家采纳,获得10
4秒前
思源应助科研通管家采纳,获得10
5秒前
wanci应助科研通管家采纳,获得10
5秒前
CodeCraft应助科研通管家采纳,获得10
5秒前
5秒前
嘻哈hang应助科研通管家采纳,获得10
5秒前
Hello应助科研通管家采纳,获得10
5秒前
5秒前
爆米花应助科研通管家采纳,获得10
5秒前
SciGPT应助科研通管家采纳,获得10
5秒前
哭泣灯泡应助科研通管家采纳,获得30
5秒前
在水一方应助科研通管家采纳,获得10
5秒前
爆米花应助科研通管家采纳,获得10
5秒前
5秒前
5秒前
5秒前
科研通AI5应助Frenda采纳,获得10
7秒前
7秒前
华仔应助yyyyy语言采纳,获得30
7秒前
hlc完成签到,获得积分10
9秒前
山止川行完成签到,获得积分10
9秒前
xiaojuexian发布了新的文献求助10
9秒前
李爱国应助勇敢的鸡屁股采纳,获得10
9秒前
10秒前
汉堡包应助默客采纳,获得10
10秒前
10秒前
高分求助中
Mass producing individuality 600
Разработка метода ускоренного контроля качества электрохромных устройств 500
Chinesen in Europa – Europäer in China: Journalisten, Spione, Studenten 500
Arthur Ewert: A Life for the Comintern 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi // Kurt Werner Radtke 500
Two Years in Peking 1965-1966: Book 1: Living and Teaching in Mao's China // Reginald Hunt 500
Epigenetic Drug Discovery 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3823778
求助须知:如何正确求助?哪些是违规求助? 3366152
关于积分的说明 10439237
捐赠科研通 3085255
什么是DOI,文献DOI怎么找? 1697277
邀请新用户注册赠送积分活动 816305
科研通“疑难数据库(出版商)”最低求助积分说明 769492